FDA approves initiation of Phase I clinical trial for cervical cancer and oropharyngeal cancer

Tessa Therapeutics’ research partner, Baylor College of Medicine (Baylor), received US Food and Drug Administration (FDA) approval in June 2015 to initiate Phase I clinical trials involving adoptive HPV-specific T Cell therapy to treat HPV-associated cervical cancer and oropharyngeal cancer. Approximately 700,000 new cases of cervical cancer and oropharyngeal cancer are diagnosed every year, with up to 70- 80% of these cases being positive for HPV.